Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Multicenter Study
. 2024 Jan;6(1):e33-e43.
doi: 10.1016/S2589-7500(23)00208-X.

End-to-end prognostication in colorectal cancer by deep learning: a retrospective, multicentre study

Affiliations
Multicenter Study

End-to-end prognostication in colorectal cancer by deep learning: a retrospective, multicentre study

Xiaofeng Jiang et al. Lancet Digit Health. 2024 Jan.

Erratum in

Abstract

Background: Precise prognosis prediction in patients with colorectal cancer (ie, forecasting survival) is pivotal for individualised treatment and care. Histopathological tissue slides of colorectal cancer specimens contain rich prognostically relevant information. However, existing studies do not have multicentre external validation with real-world sample processing protocols, and algorithms are not yet widely used in clinical routine.

Methods: In this retrospective, multicentre study, we collected tissue samples from four groups of patients with resected colorectal cancer from Australia, Germany, and the USA. We developed and externally validated a deep learning-based prognostic-stratification system for automatic prediction of overall and cancer-specific survival in patients with resected colorectal cancer. We used the model-predicted risk scores to stratify patients into different risk groups and compared survival outcomes between these groups. Additionally, we evaluated the prognostic value of these risk groups after adjusting for established prognostic variables.

Findings: We trained and validated our model on a total of 4428 patients. We found that patients could be divided into high-risk and low-risk groups on the basis of the deep learning-based risk score. On the internal test set, the group with a high-risk score had a worse prognosis than the group with a low-risk score, as reflected by a hazard ratio (HR) of 4·50 (95% CI 3·33-6·09) for overall survival and 8·35 (5·06-13·78) for disease-specific survival (DSS). We found consistent performance across three large external test sets. In a test set of 1395 patients, the high-risk group had a lower DSS than the low-risk group, with an HR of 3·08 (2·44-3·89). In two additional test sets, the HRs for DSS were 2·23 (1·23-4·04) and 3·07 (1·78-5·3). We showed that the prognostic value of the deep learning-based risk score is independent of established clinical risk factors.

Interpretation: Our findings indicate that attention-based self-supervised deep learning can robustly offer a prognosis on clinical outcomes in patients with colorectal cancer, generalising across different populations and serving as a potentially new prognostic tool in clinical decision making for colorectal cancer management. We release all source codes and trained models under an open-source licence, allowing other researchers to reuse and build upon our work.

Funding: The German Federal Ministry of Health, the Max-Eder-Programme of German Cancer Aid, the German Federal Ministry of Education and Research, the German Academic Exchange Service, and the EU.

PubMed Disclaimer

Conflict of interest statement

Declaration of interests JNK has received consulting fees from Owkin; DoMore Diagnostics; Panakeia; and Histofy; furthermore, JNK holds shares and holds a leadership role in StratifAI and has received honoraria for lectures by Bayer, Eisai, Merck Sharp & Dohme (MSD), Bristol-Myers Squibb (BMS), Roche, Pfizer, and Fresenius and has participated on a Data Safety Monitoring Board or Advisory Board for Bayer, Eisai, MSD, BMS, Roche, and Pfizer. PQ and NPW declare research funding from Roche and PQ consulting and speaker services for Roche. JJ declares consulting fees from WHO (Development of Digital Health Solution) and CARE International, Papua New Guinea (Development of Survey Instruments). SF declares grants and contracts from Bundesministerium für Bildung und Forschung, Deutsche Forschungsgemeinschaft, and German Cancer Aid, and payment or honoraria from BMS, MSD, European Society for Medical Oncology, and Deutsche Gesellschaft für Pathologie. DT holds shares in StratifAI. WM is a shareholder of Gemeinschaftspraxis Pathologie Starnberg, a private pathology practice in Germany. All other authors declare no competing interests.

References

Publication types